CVS - CVS Health Corporation

NYSE - NYSE Delayed Price. Currency in USD
52.93
-0.03 (-0.06%)
At close: 4:01PM EDT

52.93 0.00 (0.00%)
After hours: 4:40PM EDT

Stock chart is not supported by your current browser
Previous Close52.96
Open52.99
Bid52.87 x 3200
Ask52.88 x 800
Day's Range52.56 - 53.11
52 Week Range51.77 - 82.15
Volume9,259,390
Avg. Volume13,975,811
Market Cap68.672B
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateMay 1, 2019
Forward Dividend & Yield2.00 (3.46%)
Ex-Dividend Date2019-04-22
1y Target Est73.04
Trade prices are not sourced from all markets
  • Temple, Aetna sign multi-year contract extension
    American City Business Journals2 hours ago

    Temple, Aetna sign multi-year contract extension

    Temple officials said the Aetna deal will help the health system expand value-based purchasing programs and quality initiatives.

  • CVS Health (CVS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks6 hours ago

    CVS Health (CVS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • MarketWatch8 hours ago

    Benchmark initiates coverage of Charlotte's Web with buy rating

    Benchmark initiated coverage of Colorado-based cannabis company Charlotte's Web Holdings Inc. with a buy rating and a $25 price target that is 25% above its current trading level. Analyst Mike Hickey listed a range of positives for the stock, including an early move advantage in the CBD market, a vertically integrated business model with a large 2018 hemp harves, and the rapid expansion of its retail network. "CWEB is a US market share leader and pure play in the CBD market, with an established brand, 4,000-plus domestic retail distribution locations and significant online sales," Hickey wrote in a note. The analyst also lauded the recent 2018 Farm bill, which legalized hemp, which he now expects will become a significant agricultural commodity. The company is expecting to benefit from the CBD market, which The Hemp Business Journal is expecting to become a nearly $7 billion market by 2023. Companies including CVS , Rite Aid and Walgreens have started selling CBD-infused products, although these are not yet allowed by the U.S. Food and Drug Administration. The FDA took over regulation of CBD from the DEA when hemp was legalized and it has said companies cannot add the substance to food or drinks for now. However, some companies have moved ahead anyway, as they are not expecting enforcement actions. Charlotte's Web shares have gained 81% in the year to date, while the S&P 500 has gained 11.9%.

  • PR Newswire8 hours ago

    CVS Health Encourages Americans to Remove Expired, Unwanted or Unused Medications From Their Homes on National Prescription Drug Take-Back Day on April 27

    WOONSOCKET, R.I., April 24, 2019 /PRNewswire/ -- As part of its commitment to helping build healthier communities, CVS Health (CVS) is reminding Americans to clean out their medicine cabinets and safely dispose of unused medication on National Prescription Drug Take-Back Day, this Saturday, April 27. According to the National Survey on Drug Use and Health, in-home medicine cabinets are often a source of diverted medications, and CVS Pharmacy recommends that patients dispose unused medicines promptly, safely, and securely.

  • ACCESSWIRE9 hours ago

    SHAREHOLDER ALERT: CVS MWA AAPL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / April 24, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...

  • ACCESSWIRE22 hours ago

    2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES / ACCESSWIRE / April 23, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 21, 2015 and February 20, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before April 26, 2019.

  • ACCESSWIRE22 hours ago

    CLASS ACTION UPDATE for CORT, CVS and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
    Zacks23 hours ago

    CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know

    CVS Health (CVS) closed at $52.96 in the latest trading session, marking a +1.01% move from the prior day.

  • ACCESSWIREyesterday

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CVS Health Corporation of Class Action Lawsuit and Upcoming Deadline – CVS

    NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against CVS Health Corporation (''CVS'' or the ''Company'') (CVS) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-01725, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired CVS Health securities between May 21, 2015 and February 20, 2019, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • PR Newswireyesterday

    CVS Pharmacy Completes Rollout of Time Delay Safes in All of Its Alabama Pharmacies

    WOONSOCKET, R.I., April 23, 2019 /PRNewswire/ -- CVS Pharmacy, the retail division of CVS Health (CVS), announced today that it has completed the rollout of time delay safes in all of its 186 CVS Pharmacy locations in Alabama. The safes are anticipated to help prevent pharmacy robberies and the diversion of controlled substance narcotic medications by keeping them out of the hands of unauthorized individuals.

  • CVS Stock Isn’t in as Much Trouble as You Might Think
    InvestorPlaceyesterday

    CVS Stock Isn’t in as Much Trouble as You Might Think

    CVS Health (NYSE:CVS) is an organization that should do well in any part of the economic cycle, since we all need medicine and healthcare products from time to time. So on paper, CVS stock has similar characteristics to Home Depot (NYSE:HD) and Procter & Gamble (NYSE:PG).Source: Mike Mozart via FlickrBut unlike those latter names, CVS and other retail pharmacy stocks have not done well over the past few years. Since August 2015, CVS has dropped over 50%. Even worse, the owners of CVS stock have nothing on the horizon to cheer about, and CVS has tumbled 20% since January.Confronting retail pharmacy stocks, including CVS, is a double whammy of potentially crippling headwinds. First, the retail pharmacy giant must address political and public anger against rising healthcare costs. After embarrassing controversies such as the "pharma bro" scandal, the American electorate will make this a pivotal issue next year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 High-Yielding Dividend Stocks That Won't Wilt Not only that, but political momentum appears to be moving further against retail pharmacy stocks. That's troubling for the owners of CVS stock. Specifically, popular presidential candidates like Bernie Sanders have supported initiatives like the "Medicare for All Act." Rising stars like Democratic and economic firebrand Andrew Yang are guaranteed to make "Medicare for All" a political talking point.That is already a huge problem for retail pharmacy stocks. But the other dark cloud impacting CVS stock is competition. I'm not just talking about individual players in a hurting sector cutting each others' throats. Rather, I'm calling out the giant gorilla in the room: Amazon (NASDAQ:AMZN).I love Amazon because it's an unrivaled American success story. But let's also be honest: Amazon's success has come at the expense of other American businesses. Now that AMZN has its eyes on retail pharmacy, it's no wonder why CVS stock is so volatile. Threats Rattle CVS, But They Won't Be FatalNo matter how you look at it, CVS stock is incredibly risky. Unfortunately, recent developments have put more pressure on CVS. But as bad as things have gotten, the headwinds facing CVS stock are not completely devastating.While the political noose appears to be tightening its grip on CVS, this dynamic also offers opportunity. Sure, CVS and other pharmacy stocks probably won't benefit anymore from overpriced prescription medicine. However, if the Democrats take over the White House next year - and that's a real possibility - millions of underserved Americans will have access to quality healthcare insurance.These Democratic policies will cause many Americans who are buying drugs in foreign countries to obtain them in the U.S. instead.Earlier this year, NPR highlighted the case of Michelle Fenner. Doctors diagnosed her son with Type 1 diabetes almost a decade ago, meaning he requires daily insulin shots to live. Last year, a three-month supply of insulin rose to $3,700.In Tijuana, Mexico, however, Fenner only has to pay an amazingly low $600. Such extraordinary discounts have inspired up to 320,000 Americans to travel abroad for healthcare reasons each year. Therefore, cost-cutting measures may initially hurt the profit margins of retail pharmacy stocks. But at the same time, the retailers would also capture revenue that previously went to foreign countries.That's not all. According to Harvard Health Publishing, millions of Americans skimp on medication because of their exorbitant costs. Again, a cap on costs would initially hurt the profit margins of pharmaceutical retailers. But in the long run, pharmacy retailers will obtain revenue from new sources, boosting CVS stock. Amazon Can't Quite Disrupt CVSAs I mentioned earlier, disruptive competition presents a serious threat to CVS stock. Amazon succeeded in disrupting multiple retail segments. Therefore, it's only natural to assume that AMZN will also cripple CVS.However, pharmacy retail is unlike other retail categories because consumers often need their medication right way. For instance, if someone has an especially explosive case of diarrhea, he's not going to wait three to five business days for a treatment to be shipped to him. Instead, he needs relief right away.As a result, I think Amazon's overall impact on pharmacies will be similar to its impact on the home-improvement sector. Home Depot (NYSE:HD) must contend with competition from the e-commerce giant. However, traditional brick-and-mortar locations serve consumers looking for home-improvement products well. They get what they want, when they want it. That attribute is much more important for people who need drugs.Having said all that, I'm not entirely gung-ho on CVS stock. The underlying company has a huge debt load. Moreover, it has struggled to adapt to its industry's changing landscape.But it's also very possible that, in the wake of the decline of CVS stock, the bad news is already reflected in the shares. Once investors realize that the bad news isn't all that terrible, CVS could rally, at least for awhile.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post CVS Stock Isna€™t in as Much Trouble as You Might Think appeared first on InvestorPlace.

  • GuruFocus.com2 days ago

    5 Worst-Performing Health Insurance Stocks of 2019

    Health care has lagged the market more than any other sector this year

  • GuruFocus.com2 days ago

    52-Week Company Lows

    According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of Bristol-Myers Squibb Company (BMY) shares has declined to close to the 52-week low of $45.52, which is 30.4% off the 52-week high of $63.69. The company has a market cap of $74.38 billion.

  • ACCESSWIRE2 days ago

    CLASS ACTION UPDATE for DPLO, CAG and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • GlobeNewswire2 days ago

    SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CVS, ARA, CTL, KHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, April 22, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.

  • GlobeNewswire2 days ago

    CLASS ACTION UPDATE for T, CAG, CVS and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, April 22, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • Better Buy: Walgreens Boots Alliance vs. CVS Health
    Motley Fool3 days ago

    Better Buy: Walgreens Boots Alliance vs. CVS Health

    Which of these major pharmacy retailers is more likely to be the bigger long-term winner?

  • GuruFocus.com4 days ago

    Stocks That Fell to 3-Year Lows in the Week of April 19

    Gilead Sciences Inc., CVS Health Corp, Macerich Co. and OPKO Health Inc. have declined to their respective three-year lows

  • Benzinga4 days ago

    Bulls And Bears Of The Week: Abbott Labs, Chevron, CVS, United And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included a leading airline and a pharmaceutical giant. And bearish calls included cruise line operators ...

  • Best Stock Pick From The 2018 Sohn Conference (Part II)
    Insider Monkey4 days ago

    Best Stock Pick From The 2018 Sohn Conference (Part II)

    Read the beginning of this article here. Nathaniel August recommended a position in Peabody Energy (NYSE:BTU) which “is the largest and least expensive way to participate in the coal market” according to this fund manager. Unfortunately the stock lost more than 26% since August’s recommendation. David Einhorn recommended a short position in Assured Guaranty (NYSE:AGO) due […]

  • GlobeNewswire5 days ago

    SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CVS, CAG, KHC, BPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, April 19, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.

  • ACCESSWIRE5 days ago

    CLASS ACTION UPDATE for CAG, CVS and AAPL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / April 19, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CVS Health Corporation- CVS
    PR Newswire5 days ago

    INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CVS Health Corporation- CVS

    NEW YORK , April 19, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CVS Health Corporation ...

  • ACCESSWIRE6 days ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CVS, EB and NTNX

    CEDARHURST, NY / ACCESSWIRE / April 18, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • ACCESSWIRE6 days ago

    IMPORTANT APRIL DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation (''CVS'' ...